Original Article

Incidence and Impact of False-Positive Urine Pneumococcal Antigen Testing in Hospitalized Patients

Authors: Patrick A. Ryscavage, MD, Gary A. Noskin, MD, Anne Bobb, BS Pharm, Laura Bardowski, RN, BSN, Teresa R. Zembower, MD, MPH

Abstract

Objectives: Immunochromatographic urine pneumococcal antigen testing (ICT) has become a common diagnostic tool for those presenting with possible invasive pneumococcal disease. The incidence and clinical impact of ICT false-positivity on hospitalized patients has not been assessed outside of specific patient subpopulations. ICT performance needs to be assessed in a real-world clinical setting. This study aims to describe the incidence and clinical impact of ICT false-positivity in a hospital setting over a 19-month period.


Methods: A retrospective cohort study was performed to assess the incidence of false-positive (FP) ICT among hospitalized patients from November 21, 2007 to June 30, 2009. The primary objective was to describe the incidence of FP ICT results. The secondary objective was to describe what clinical impact, if any, could be attributed to FP ICT results.


Results: During the study period, 52 positive ICT results were obtained, of which 5 (9.6%) were deemed falsely positive. Interestingly, two of the 5 FP results were from patients who had received 23-valent pneumococcal vaccine (PPV) in the 2 days prior to ICT. The management of all 5 patients was impacted by the FP results through unnecessary antimicrobial treatment and/or deferral of further clinical evaluation.


Conclusion: Health care providers should be aware of the potential for ICT FP and should order and interpret these tests within an informed clinical framework.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. File TM. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med 2004;117(3A suppl):39S-50S.
 
2. Adegbola RA, Obaro SK, Biney E, et al. Evaluation of BinaxNOW Streptococcus pneumoniae urinary antigen test in children in a community with a high carriage rate of pneumococcus. Pediatr Infect Dis J2001;20:718-719.
 
3. Andreo F, Prat C, Ruiz-Manzano J, et al. Persistence of Streptococcus pneumoniae urinary antigen excretion after pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2009;28:197-201.
 
4. Domínguez J, Galí N, Blanco S, et al. Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest 2001;119:243-249.
 
5. Dowell SF, Garman RL, Liu G, et al. Evaluation of BinaxNOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients. Clin Infect Dis 2001;32:824-825.
 
6. Gutierrez F, Masiá M, Rodríguez JC, et al. Evaluation of the immunochromatographic BinaxNOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003;36:286-292.
 
7. Hamer DH, Egas J, Estrella B, et al. Assessment of the BinaxNOW Streptococcus pneumoniaeurinary antigen test in children with nasopharyngeal pneumococcal carriage. Clin Infect Dis2002;34:1025-1028.
 
8. Ishida T, Hashimoto T, Arita M, et al. A 3-year prospective study of a urinary antigen-detection test for Streptococcus pneumoniae in community-acquired pneumonia: utility and clinical impact on the reported etiology. J Infect Chemother 2004;10:359-363.
 
9. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(2 suppl):S27-S72.
 
10. Marcos, MA, Jiménez de Anta MT, de la Bellacasa JP, et al. Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults. Eur Respir J 2003;21:209-214.
 
11. Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001;39:3495-3498.
 
12. Navarro D, García-Maset L, Gimeno C, et al. Performance of the BinaxNOW Streptococcus pneumoniae urinary antigen assay for diagnosis of pneumonia in children with underlying pulmonary diseases in the absence of acute pneumococcal infection. J Clin Microbiol 2004;42:4853-4855.
 
13. Smith MD, Derrington P, Evans R, et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the BinaxNOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol 2003;41:2810-2813.
 
14. Kelley R, Keyserling H. Antigen excretion in the urine after pneumococcal vaccination. Pediatr Infect Dis J 1997;16:720.
 
15. Priner M, Cornillon C, Forestier D, et al. Might Streptococcus pneumoniae urinary antigen test be positive because of pneumococcal vaccine? J Am Geriatr Soc 2008;56:170-171.
 
16. Rosón B, Fernández-Sabé N, Carratalà J, et al. Contribution of a urinary antigen assay (BinaxNOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis 2004;38:222-226.
 
17. Sordé R, Falcó V, Lowak M, et al. Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Int Med 2011;171:166-172.
 
18. Musher DM. Streptococcus pneumoniae. In: Mandell GL, Bennett J, Dolin R, eds. Principles and Practice of Infectious Disease. Philadelphia, PA: Elsevier; 2010.
 
19. Binax Laboratory, Inc. BinaxNOW Streptococcus pneumoniae Test [package insert]. Scarborough, ME: Binax Inc; 2008.
 
20. Nicoletti C, Brandileone MC, Guerra ML, et al. Prevalence, serotypes, and risk factors for pneumococcal carriage among HIV-infected adults. Diagn Microbiol Infect Dis 2007;57:259-265.
 
21. Vazquez EG, Marcos MA, Vilella A, et al. Assessment of a commercial rapid urinary antigen test to detect Streptococcus pneumoniae in patients who received 23-valent pneumococcal polysaccharide vaccine. Eur J Clin Microbiol Infect Dis 2004;23:927-929.
 
22. Centers for Medicare and Medicaid Services. QMIS: Measure Details. Available at: https://www.cms.hhs.gov/apps/QMIS/measure_details.asp?id=599. Accessed January 5, 2010.
 
23. Department of Health and Human Services, Centers for Medicare & Medicaid Services. October 2, 2002. Medicare and Medicaid Programs; Conditions of Participation: Immunization Standards for Hospitals, Long Term Care Facilities, and Home Health Agencies. 42 CFR Parts 482, 483 and 484.Federal Register Vol. 67(191): Rules and Regulations.
 
24. Shorr AF, Owens RC Jr. Guidelines and quality for community-acquired pneumonia: measures from the Joint Commission and the Centers for Medicare and Medicaid Services. Am J Health Syst Pharm2009;66:S2-S7.
 
25. Walls RM, Resnick J. The Joint Commission on Accreditation of Healthcare Organizations and Center for Medicare and Medicaid Services community-acquired pneumonia initiative: what went wrong? Ann Emerg Med 2005;46:409-411.